This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, H. Articles by Imai, K. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, H. Articles by Imai, K.

Genetic and Clinical Features of Human Pancreatic Ductal Adenocarcinomas with Widespread Microsatellite Instability¹

First Department of Internal Medicine [H. Y., F. I., H. N., H. F., S. S., K. I.], Sapporo Medical University, Sapporo 060-8543, Japan, and The Burnham Institute, La Jolla, California 92037 [M. P.]

The incidences of microsatellite instability (MSI) and underlying DNA mismatch repair (MMR) defects in pancreatic carcinogenesis have not been well established. We analyzed 100 sporadic and 3 hereditary pancreatic ductal adenocarcinomas for MSI, and high-frequency MSI (MSI-H) and low-frequency MSI (MSI-L) tumors were further analyzed for frameshift mutations of possible target genes and for promoter methylation and mutation of DNA MMR genes, including hMLH1, hMSH2, hMSH3, and hMSH6 genes. Among the 100 sporadic tumors, 13 (13%) were MSI-H, 13 (13%) were MSI-L, and 74 (74%) were microsatellite stable (MSS) tumors. All of the three hereditary tumors from hereditary nonpolyposis colorectal cancer (HNPCC) patients were MSI-H. MSI-H tumors were significantly associated with poor differentiation and the presence of wild-type K-RAS and p53 genes. Patients with MSI-H tumors had a significantly longer overall survival time than did those with MSI-L or MSS tumors (P = 0.0057). Frameshift mutations of hMSH3, hMLH3, BRCA-2, TGF-ß type II receptor, and BAX genes were detected in MSI-H tumors. Hypermethylation of the hMLH1 promoter was observed in 6 (46%) of the 13 sporadic MSI-H tumors but not in any of the 3 hereditary MSI-H tumors or 13 MSI-L tumors. All of the 3 HNPCC cases had germ-line hMLH1 mutation accompanied by loss of heterogeneity or other mutation in the tumor. Our results suggest that pancreatic carcinomas with MSI-H represent a distinctive oncogenic pathway because they exhibit peculiar clinical, pathological, and molecular characteristics. Our results also suggest the principal involvement of epigenetic or genetic inactivation of the hMLH1 gene in the pathogenesis of pancreatic carcinoma with MSI-H.

This article has been cited by other articles:

				K. Imai and H. Yamamoto Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics Carcinogenesis, April 1, 2008; 29(4): 673 - 680. [Abstract] [Full Text] [PDF]

				F. J. Couch, M. R. Johnson, K. G. Rabe, K. Brune, M. de Andrade, M. Goggins, H. Rothenmund, S. Gallinger, A. Klein, G. M. Petersen, et al. The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 342 - 346. [Abstract] [Full Text] [PDF]

				J. Earl, L. Yan, L. J. Vitone, J. Risk, S. J. Kemp, C. McFaul, J. P. Neoptolemos, W. Greenhalf, for the European Registry of Hereditary Pancreatit, R. Kress, et al. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1948 - 1955. [Abstract] [Full Text] [PDF]

				C. Beger, M. Ramadani, S. Meyer, G. Leder, M. Kruger, K. Welte, F. Gansauge, and H. G. Beger Down-Regulation of BRCA1 in Chronic Pancreatitis and Sporadic Pancreatic Adenocarcinoma Clin. Cancer Res., June 1, 2004; 10(11): 3780 - 3787. [Abstract] [Full Text] [PDF]

				B. Nakata, Y. Qing Wang, M. Yashiro, N. Nishioka, H. Tanaka, M. Ohira, T. Ishikawa, H. Nishino, and K. Hirakawa Prognostic Value of Microsatellite Instability in Resectable Pancreatic Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2536 - 2540. [Abstract] [Full Text] [PDF]

				H. Han, D. J. Bearss, L. W. Browne, R. Calaluce, R. B. Nagle, and D. D. Von Hoff Identification of Differentially Expressed Genes in Pancreatic Cancer Cells Using cDNA Microarray Cancer Res., May 1, 2002; 62(10): 2890 - 2896. [Abstract] [Full Text] [PDF]